Latest news with #MonogramTechnologiesInc
Yahoo
16-05-2025
- Business
- Yahoo
Monogram Technologies Inc (MGRM) Q1 2025 Earnings Call Highlights: FDA Clearance and Strategic ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Monogram Technologies Inc (NASDAQ:MGRM) received FDA clearance for their embossed total TKA system, marking a significant milestone in the company's history. The company has a strong balance sheet with $13.3 million in cash and no traditional debt, providing financial stability. Monogram Technologies Inc (NASDAQ:MGRM) has reduced its monthly cash burn rate from $1.1-$1.2 million to $0.8 million, reflecting improved cost management. The company is set to initiate a groundbreaking multi-center clinical trial in India for autonomous saw-based robotic total knee surgeries. Monogram Technologies Inc (NASDAQ:MGRM) is actively showcasing its system to key opinion leaders and preparing for additional placements, indicating strong future growth potential. The company anticipates a slow and methodical initial rollout, which may delay immediate commercial traction. Monogram Technologies Inc (NASDAQ:MGRM) faces significant competition from established players like Stryker, which holds a dominant market share. The company requires additional capital to accelerate growth, indicating potential future funding needs. There are still technical and regulatory hurdles to overcome in both the US and India, which could impact timelines. The company's commercial success is heavily dependent on surgeon adoption and the ability to demonstrate the system's value proposition in real-world settings. Warning! GuruFocus has detected 9 Warning Signs with NSFDF. Q: Can you provide more detail on the timelines for technical and regulatory hurdles in the US and India? A: Unidentified_3: We expect to perform live patient surgeries in India within 90 business days, and the clinical trial system is on its way to India. In the US, our first placement is underway, and we anticipate it will be a reality in the operating room by Q3 2025. Q: How does Monogram plan to differentiate itself from Stryker's Mako system, particularly in terms of surgeon adoption? A: Unidentified_3: We aim to be competitive with Mako by focusing on accuracy, safety, and efficiency. Our system is designed to minimize surgeon fatigue and improve tensioning. We also have an AI-based preoperative pipeline for landmark identification, which we believe will be a small advantage over Mako. Q: What feedback have you received from key opinion leaders (KOLs) regarding the Monogram system? A: Unidentified_3: Initially, feedback was that the system was interesting but slow. Over time, we've improved speed and accuracy, and now surgeons are impressed with our progress. Surgeons familiar with Mako find our workflow intuitive. Q: Can you provide more details on the system enhancements being made? A: Unidentified_3: Since our FDA submission in July, we've made significant enhancements to the feed rate, end effector, blade, and software. These improvements allow for faster cutting, and we are conducting internal testing to ensure safety and performance. Q: How do you plan to manage the balance between a controlled rollout and the need for commercial traction and revenue growth? A: Unidentified_3: Our growth trajectory depends on capital access and strategic direction. We focus on high utilization of placed robots and aim to convert 100% of a surgeon's business to our system. We prioritize quality service and support for surgeons. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
05-03-2025
- Business
- Associated Press
Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025
AUSTIN, TX / ACCESS Newswire / March 5, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ('Monogram' or the 'Company'), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will participate in the 37th Annual ROTH Conference at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025. Mr. Sexson and Mr. Knape will hold one-on-one meetings with institutional investors on site during this annual invitation-only event. 37th Annual ROTH Conference Date: March 16-18, 2025 Location: Laguna Cliffs Marriott Resort & Spa in Dana Point, CA Attendees: Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape Format: In-person 1x1's Conference Website: Click here For more information on the 37th Annual ROTH Conference or to schedule a one-on-one meeting with Monogram management, please contact your conference representative or you may also email your request to [email protected] or call Chris Tyson at (949) 491-8235. About Monogram Technologies Inc. Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored. Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances. The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation. To learn more, visit Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties.. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Executive Vice President MZ North America
